19-nor-26,27-bishomo-vitamin D3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3370-3375

  Kubota, Tetsuya ^a   Koshizuka, Kozo ^a   Koike, Michiaki ^a   Uskokovic, Milan ^b   Miyoshi, Isao ^c   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXY 16,23 DIENE 26,27 BISHOMO 19 NORVITAMIN D3; 19 NOR 26,27 BISHOMO VITAMIN D3 DERIVATIVE; CALCITRIOL; CALCITRIOL DERIVATIVE; FLUORINE DERIVATIVE; RO 25 6760; RO 25 8584; RO 25 9022; RO 26 9737; RO 27 0256; RO 27 2013; RO 27 2014; RO 27 2015; RO 27 2735; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN HL 60; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG POTENCY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCITRIOL; CALCIUM; CELL CYCLE; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032146179     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Warrell, R. P., Jr., Frankel, S. R., Miller, W. H., Jr., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., Gabrilove, J., Gordon, M. S., and Dmitrovsky, E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med., 324: 1385-1393, 1991.
2. Castaigne, S., Chomienne, C., Daniel, M. T., Ballerini, P., Berger, R., Fenaux, P., and Degos, L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, 76: 1704-1709, 1990.
3. Reichel, H., Koeffler, H. P., and Norman, A. W. The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med., 320: 980-991, 1989.
4. Niles, R. M. Use of vitamin A and D in chemoprevention and therapy of cancer: Control of nuclear receptor expression and function. Vitamins, cancer and receptors. Adv Exp. Med. Biol., 375: 1-15, 1995.
5. 3 on primary cultures of human prostatic cells. Cancer Res., 54: 805-810, 1994.
6. 3. Endocrinology, 136: 20-26, 1995.
7. Danielpour, D., Kadomatsu, K., Anzano, M. A., Smith, J. M., and Sporn, M. B. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res., 54: 3413-3421, 1994.
8. 3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J. Cell. Biochem., 66: 413-425, 1997.
9. Eisman, J. K., Martin, T. J., MacIntyre, I., and Moseley, J. M. 1,25-Dihydroxyvitamin-D receptor in breast cancer cells. Lancet, 2: 1335-1336, 1979.
10. Framptom, R. J., Omond, S. A., and Eisman, J. A. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin-D metabolites. Cancer Res., 43: 443-447, 1983.
11. Colston, K. W., Chander, S. K., MacKay, A. G., and Coombes, R. C. Effects of synthetic vitamin D analogs on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol., 44: 693-702, 1992.
12. Bower, M., Colston, K. W., Stein, R. C., Hedley, A., Gazet, J-C., Ford, H. T., and Coombes, R. C. Topical calcipotriol treatment in advanced breast cancer. Lancet, 337: 701-702, 1991.
13. 3 on the morphology of human breast cancer cell line BT-20. Differentiation, 40: 63-69, 1989.
14. 3. Proc. Natl. Acad. Sci. USA, 78: 4990-4994, 1981.
15. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc. Natl. Acad. Sci. USA, 80: 201-204, 1983.
16. 3 prolongs survival time of leukemic mice. Proc. Natl. Acad. Sci. USA, 87: 3929-3932, 1990.
17. 3: differential effects on leukemic cell growth, differentiation, and intestinal absorption. Cancer Res., 50: 6857-6864, 1990.
18. 3, inhibits azoxymethane-induced colonic tumorigenesis. Cancer Res., 55: 3050-3054, 1995.
19. 3. Cancer Res., 54: 4057-4064, 1994.
20. Yu, J., Papavasiliou, V., Rhim, J., Goltzman, D., and Kremer, R. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anticancer Drugs, 6: 101-108, 1995.
21. 3: towards an endocrine therapy of brain tumors? J. Neurosci. Res. 37: 271-277, 1994.
22. 3: In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat. Rep., 69: 1399-1407, 1985.
23. 3, inhibits the growth of human breast cancer in vitro without causing hypercalcemia. Endocrinology, 129: 832-837, 1991.
24. 3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood, 78: 75-82, 1991.
25. 3 is a potent anti-leukemic agent with low potential to cause hypercalcemia. Leukemia Res., 18: 453-463, 1994.
26. 3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels. Leukemia Res., 19: 65-72, 1995.
27. 3: a novel class of potent inhibitors of proliferation of human breast cell lines. Cancer Res., 57: 4545-4550, 1997.
28. kip1 and E-cadherin J. Mol. Endocrinol., 19: 15-27, 1997.
29. Munker, R., Kobayashi, T., Elstner, E., Norman, A. W., Uskokovic, M., Zhang, W., Andreeff, M., and Koeffler, H. P. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood, 88: 2201-2209, 1996.
30. 3 analogs: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res., 55: 2822-2830, 1995.
31. 3 analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood, in press, 1998.
32. 3 and its fluorinated analogs. Cancer Res., 44: 5624-5628, 1984.
33. Inaba, M., Okuno, S., Nishizawa, Y., Imanishi, Y., Katsumata, T., Sugata, I., and Morii, H. Effect of substituting fluorine for hydrogen at C-26 and C-27 on the side chain of 1,25-dihydroxyvitamin D3. Biochem. Pharmacol 45: 2331-2336, 1993.
34. Zhou, J., Norman, A. W., Lübert, M., Collins, E. D., Uskokovic, M. R., and Koeffler, H. P. Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood, 74: 82-93, 1989.
35. Uskokovic, M. R., Studzinski, G. P., Gardner, J. P., Reddy, S. G., Campbell, M. J., and Koeffler, H. P. The 16-ene vitamin D analogs. Curr. Pharmaceutical Design, 3: 99-123, 1997.
36. 3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood, 84: 1960-1967, 1994.
37. 3 in HL-60 cells. Cancer Res., 56: 264-267, 1996.